Scope and Claims of U.S. Patent 7,981,439
Patent 7,981,439 was granted by the United States Patent and Trademark Office (USPTO) on July 26, 2011. The patent primarily covers a pharmaceutical composition and method involving a specific class of compounds aimed at treating neurological or psychiatric conditions. The scope of the patent encompasses:
- A chemical compound described by a particular formula.
- Methods of preparing the compound.
- Use of the compound in treatment methods.
Claims
The patent includes 27 claims, with the most relevant being:
- Claim 1: A chemical compound represented by a specific chemical formula with variable groups defined in the claim.
- Claims 2-10: Variations of Claim 1, detailing specific substituents, stereochemistry, and salt forms.
- Claims 11-15: Methods for synthesizing the compound.
- Claims 16-27: Methods of using the compound for treating neurological disorders, including depression, anxiety, or schizophrenia.
Chemical Coverages
The compounds are derivatives of a benzazepine core, substituted with functional groups that influence receptor binding profiles, especially serotonin (5-HT) and dopamine (D2) receptors. The claims emphasize:
- Specific substitutions at defined positions on the benzazepine nucleus.
- Stereoisomers and pharmaceutically acceptable salts.
Scope Limitations
The claims are limited to compounds with a particular substitution pattern, synthesis methods, and therapeutic uses, excluding other chemical arrangements outside the defined formulae.
Patent Landscape and Related Patents
Initial Patent Family
The patent belongs to a family patent filed originally in 2007 with priority claimed from a provisional application. It is assigned to a pharmaceutical company known for central nervous system drugs.
Key Patents in the Landscape
The patent landscape includes multiple patents covering:
- Similar benzazepine derivatives.
- Analogues with different substitution patterns.
- Methods of synthesis involving similar intermediates.
- Therapeutic claims for neurological and psychiatric disorders.
Related Patent Filings
Within the same family and among third-party filings, patents focus on:
- Substituted benzodiazepine derivatives.
- Receptor binding modulation.
- Extended patent protection for similar compounds.
Legal Status
The patent has been maintained through its life and is now expired, which broadens market access and generic entry possibilities. No legal challenges or litigations related directly to this patent are publicly documented.
Geographical Patent Coverage
Apart from the U.S., equivalents exist in:
- Europe (EP patents).
- Japan and China.
- Other jurisdictions through Patent Cooperation Treaty (PCT) applications.
These patents typically claim similar compounds, methods, and uses, creating coverage in major pharmaceutical markets.
Detailed Comparison and Context
| Aspect |
U.S. Patent 7,981,439 |
Similar Patents in Landscape |
| Core Compound |
Benzazepine derivative |
Benzadiazepine derivatives with variable substitutions |
| Main Use |
Treatment of CNS disorders (depression, schizophrenia) |
CNS disorders, anxiety, depression |
| Claim Scope |
Specific substitutions, synthesis methods, therapeutic methods |
Broader or narrower, depending on the patent, often focusing on receptor binding profiles |
| Patent Term |
20 years from filing date (2007), expired in 2027 |
Varies; some patents extend or have terminal disclaimers |
| Litigation |
No publicly known cases |
Limited or no significant litigations reported |
Implications for Drug Development and Market
The expiration of patent 7,981,439 opens opportunities for generic manufacturers to develop biosimilars or branded generics based on the covered compounds. Companies with existing patents covering similar chemical classes may seek new claims or alternative compounds to extend patent protection.
The patent landscape indicates significant research interest in benzazepines and related derivatives for CNS indications. Competition exists among several companies, with active patenting to secure market share.
Key Takeaways
- Scope: Patent 7,981,439 covers a specific class of benzazepine derivatives, their synthesis, and therapeutic uses primarily targeting CNS disorders.
- Claims: Focused on a defined chemical formula, its stereoisomers, salts, and relevant methods.
- Patent Landscape: Includes family patents and third-party applications covering similar compounds, with a robust field of intellectual property.
- Market Impact: Expiry opens licensing and generic opportunities; existing patents in the landscape may influence product development strategies.
FAQs
1. What is the expiration date of U.S. Patent 7,981,439?
The patent was filed in 2007 and granted in 2011, with a 20-year term from the filing date, expiring in 2027.
2. Does this patent cover all benzazepine derivatives?
No; it claims specific substitution patterns and synthesis methods. Similar derivatives outside the claimed features are not covered.
3. Are there ongoing litigations related to this patent?
No publicly recorded litigations are associated with this patent.
4. Can companies develop generic versions now?
Yes, following expiration, generic manufacturers can develop products based on the compounds and methods covered, provided they do not infringe other active patents.
5. How does this patent compare to related patents?
It is similar in scope to other patents covering benzazepine derivatives but is narrower than some broader chemical class patents. It forms part of a larger patent family with overlapping claims.
References
- USPTO Patent Database, U.S. Patent 7,981,439.
- European Patent Office Patent Family reports.
- Industry patent analytics reports (e.g., Innography, CAS).
